Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (36 quarters reported)
$146M in Q4 2014 → $29.2M now. Hover for any quarter.
As reported for the quarter ended September 30, 2023. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| 10x Genomics, Inc. | 100.0% | Unchanged | 708,528 | $29.2M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2023 · filed November 13, 2023
No position changes this quarter.
quarter ended June 30, 2023 · filed August 11, 2023
No position changes this quarter.
quarter ended March 31, 2023 · filed May 12, 2023
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| 10x Genomics, Inc. | Trimmed | −650,000 | −$36.3M | 100.0% |
quarter ended December 31, 2022 · filed February 13, 2023
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| 10x Genomics, Inc. | Trimmed | −395,000 | −$14.4M | 100.0% |
quarter ended September 30, 2022 · filed November 14, 2022
No position changes this quarter.
quarter ended June 30, 2022 · filed August 12, 2022
No position changes this quarter.
quarter ended March 31, 2022 · filed May 13, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| E Epizyme, Inc. | Exited | −690,002 | −$1.73M | — |
quarter ended December 31, 2021 · filed February 11, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Novavax, Inc. | Exited | −67,373 | −$14M | — |
| AP Acceleron Pharma Inc. | Exited | −45,884 | −$7.9M | — |
| E Epizyme, Inc. | Trimmed | −142,334 | −$356K | 0.7% |
Loading...
